Finwire 29 October - 15:14

Lipum: Progress towards the next phase - VH Corp

• Final patient dosed in the phase I study
• Production process of SOL-116 according to plan
• Adjusting the WACC leads to a new fair value of SEK 15.19 (10.81) per share

During the third quarter, Lipum reported continued progress in its clinical programme with the drug candidate SOL-116 in rheumatoid arthritis (RA). Most significantly, the last patient in the ongoing phase I study was included and dosed. This means all participants and patients have been included and the study advances towards completion.

In summary, the model changes have led to a higher fair value, SEK 15.19 (10.81) per share.

Senaste nyheterna

Se alla
Finwire 8 November - 19:16
Antalet aktiva olje- och gasriggar i Kanada sjönk till 207 stycken (213)
Totala antalet aktiva olje- och gasriggar i Kanada sjönk under senaste rapportveckan. Det visar...
Finwire 8 November - 19:15
Antalet aktiva olje- och gasriggar i USA var oförändrade vid 585
Totala antalet aktiva olje- och gasriggar i USA var oförändrade under senaste rapportveckan. Det...
Finwire 8 November - 17:38
Tydlig nedgång på Stockholmsbörsen, OMXS30-index sjönk 1 procent
Stockholmsbörsen inledde veckans sista handelsdag avvaktande för att sedan bege sig nedåt mot...